The Effect of Nexpowder in Reducing Post‐ESD Coagulation Syndrome in Proximal Colon Lesions: A Retrospective Multicenter Study Authors: Won Myung Lee, Jongbeom Shin, Gyeol Seong, Boram Cha, Jin Hee Maeng, Kye Sook Kwon, Bong Min Ko Published: 2026 ABSTRACT ABSTRACTBackgroundEndoscopic submucosal dissection (ESD) is an established curative treatment for lateral spreading tumors and early colorectal cancer, but it can cause procedure‐related complications such as post‐ESD coagulation syndrome (PECS), which may increase healthcare utilization, prolong hospitalization, and raise medical costs. Nexpowder (Nextbiomedical Co. Ltd., Incheon, Republic of Korea), a highly adhesive hemostatic powder approved by the U.S. FDA for nonvariceal upper gastrointestinal bleeding, has demonstrated efficacy in preventing rebleeding. This study aimed to evaluate the prophylactic efficacy of Nexpowder in preventing PECS after colorectal ESD for high‐risk proximal lesions.MethodsThis retrospective multicenter study included patients who underwent colorectal ESD between April 2023 and October 2024 for PECS high‐risk lesions, excluding those with perforation, muscular injury, or prophylactic clipping. Nexpowder was applied prophylactically in 35 patients (46.7%), while 40 patients (53.3%) served as controls. PECS was defined as postprocedural abdominal pain, fever, and elevated inflammatory markers requiring antibiotics.ResultsPECS occurred in nine patients overall. The incidence was significantly lower in the Nexpowder group (2.9% [CI 0.3–12.6]) than in the control group (20.0% [CI 9.9–34.2]; p = 0.032). All cases resolved with conservative treatment, and no surgical intervention was required.ConclusionThe application of Nexpowder was associated with a significant reduction in the incidence of PECS after high‐risk colorectal ESD. This study provides the first clinical evidence that a topical barrier agent may serve as a simple and effective preventive strategy for PECS. Introduction Colorectal cancer (CRC) remains a major global health problem due to its high prevalence and associated mortality [1]. As CRC screening programs become more widely implemented [2, 3], the use of endoscopic treatments for colorectal neoplasms has also increased [4, 5]. Endoscopic submucosal dissection (ESD) is recommended as a standard treatment for colon neoplasms and provides excellent long‐term survival [6, 7, 8]. While generally safe, ESD carries risks of adverse events, including bleeding, perforation, and other procedure‐related complications [7, 9, 10]. Post‐ESD coagulation syndrome (PECS) is a relatively common complication, with reported incidence rates of 2.6%–21.4% [11, 12]. Clinically, PECS presents with abdominal pain and fever, requiring differentiation from perforation. Although conservative management with antibiotics and fasting is usually sufficient, it still demands considerable medical resources [11, 12]. Various preventive strategies have been explored to alleviate post‐ESD discomfort, including mechanical closure techniques (e.g., endoscopic clips and endoloops) and local application of hemostatic agents [13, 14, 15]. However, results have been inconclusive. For instance, Nomura et al. [16] reported that complete closure of post‐ESD ulcers with endoscopic clips failed to demonstrate a significant preventive effect. Similarly, a pilot study by Tsuji et al. [17] using polyglycolic acid sheets and fibrin glue showed potential but was limited by a very small sample size, precluding definitive conclusions. In the absence of an established prophylactic method, prevention has largely relied on the endoscopist's skill to minimize electrothermal injury. This gap highlights the need for a simple, reliable strategy to prevent PECS, particularly in high‐risk patients. Nexpowder (Nextbiomedical Co. Ltd., Incheon, South Korea) is a highly adhesive hemostatic powder composed of a biocompatible natural polymer (Figure 1). It has demonstrated high immediate hemostatic success in nonvariceal upper gastrointestinal bleeding (NVUGIB) and tumor‐associated bleeding [18, 19], leading to U.S. Food and Drug Administration (FDA) approval for NVUGIB (510(k) No. K240994) [20]. Recent studies have also reported its efficacy in preventing rebleeding in NVUGIB patients, which highlights its ability to form a stable physical barrier [21]. Additionally, Nexpowder may exert antimicrobial effects via its lysine‐derived polymer components [22, 23], which could help reduce adverse events after colorectal ESD. However, clinical evidence specifically evaluating its preventive efficacy against post‐ESD complications in the colon remains limited. Nexpowder (A) and powder delivery devices (B). The objective of this study was to evaluate the effectiveness of Nexpowder in preventing PECS after colonic ESD. Methods Study Patients and Ethics Patients with colorectal neoplasms, who underwent ESD between April 2023 and October 2024 at Inha University Hospital, Nowon Eulji Medical Center and Soonchunhyang University Bucheon Hospital, were retrospectively enrolled to evaluate the efficacy and safety of Nexpowder in preventing PECS. Exclusion criteria included: (1) age <19 or >80 years; (2) presence of hematologic disorders; (3) severe dysfunction of the heart, lungs, or kidneys; (4) tumors located in the distal colon or rectum; (5) simultaneous resection of two or more lesions; (6) endoscopically confirmed muscle layer injury or perforation during the ESD procedure; (7) baseline vital signs with numerical rating scale (NRS) > 2, body temperature > 37.0°C, or white blood cell (WBC) count above normal range; (8) pregnancy; and (9) application of through‐the‐scope clips at the ESD site. A total of 75 patients met the inclusion criteria (Figure 2). Medical records were reviewed to collect clinical information, including the use of antiplatelet or anticoagulant agents, tumor location and size, ESD procedure time, procedure‐related complications, and histopathologic findings. Patients were allocated based on Nexpowder application after ESD: the control group (n = 40, 53.3%) and the Nexpowder group (n = 35, 46.7%). The study protocol was approved by the institutional review board of Soonchunhyang University Bucheon Hospital (SCHBC 2025‐07‐012). Patient selection flowchart of the study. Endoscopic Procedures and Outcome Measurements Endoscopic procedures were performed by five experienced endoscopists, each with over 100 ESD cases. A VIO 300D or 200D electrosurgical unit (ERBE, Tübingen, Germany) was used, with the following settings: Endocut I mode (effect 2–3, duration 3, interval 2–3) for mucosal incision; Swift Coag mode (effect 2–3, 40–50 W) for submucosal dissection; and Soft Coag mode (effect 6–7, 60–80 W) for hemostasis. Carbon dioxide insufflation was used in all procedures, and air reduction with a rectal tube was not routinely performed. Application of Nexpowder was determined at the discretion of the endoscopist in patients who experienced intraprocedural bleeding, or in whom extensive prophylactic coagulation was performed. Nexpowder was applied to the post‐ESD ulcer site via a spraying device and catheter until the ulcer base was fully covered (Figure 3). In patients receiving Nexpowder, the endoscopic field was observed for approximately 1 min after application to ensure no powder‐related complications, such as perforation, before concluding the procedure. All patients had daily NRS pain scores and body temperature monitored for at least 3 days post‐ESD. PECS occurrence was evaluated based on clinical findings and medical record review. On post‐ESD day 1, WBC counts and C‐reactive protein (CRP) levels were measured in all patients. In cases diagnosed with PECS, serial abdominal radiographs were obtained to rule out free air. Endoscopic images demonstrating Nexpowder application in a post‐ESD ulcer. (A) A nongranular homogeneous lateral spreading tumor was identified in the proximal ascending colon. (B) Mucosal incision and submucosal dissection were performed using a dual knife. Intraprocedural bleeding occurred during ESD and was controlled through coagulation. Post‐coagulation changes were observed at the ESD site (yellow arrow). (C) En bloc resection was successfully achieved without complications. (D) Five minutes after Nexpowder application, the material was firmly attached to the post‐ESD ulcer site. Definition and Clinical Assessment of PECS PECS was defined as at least one of the following within 1–7 days after ESD: abdominal pain with NRS ≥ 4 from baseline, fever ≥ 37.5°C, or leukocytosis (WBC count > 10 000/μL) [16]. Patients meeting these criteria who received antibiotics but had no extraluminal air on imaging were diagnosed with PECS finally. Post‐ESD bleeding was defined as a hemoglobin decrease ≥ 2 g/dL from baseline or overt gastrointestinal bleeding, such as hematochezia, within 30 days following ESD [24]. Based on the clinical criteria, PECS was diagnosed in patients with persistent abdominal pain and fever lasting for more than 6 h who required antibiotic therapy, in the absence of extraluminal air on imaging studies. Transient symptoms resolving within 6 h without intervention, or asymptomatic laboratory abnormalities alone were not considered PECS, reflecting the real‐world practice. Statistical Analyses Continuous variables were summarized as medians with ranges, and categorical variables as counts and percentages. Group comparisons were performed using the Mann–Whitney U test, Student's t‐test, chi‐square test, or Fisher's exact test, as appropriate. To identify factors associated with PECS, univariable and multivariable logistic regression analyses were performed. Variables including age, sex, antithrombotic medications, tumor size, en bloc resection, time of procedure, and the use of Nexpowder were included in the multivariable model. The results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Two‐sided p values < 0.05 were considered statistically significant. All analyses were conducted using SPSS version 25.0 (IBM Corp., Armonk, NY, USA). Results Patients and Bleeding Characteristics Baseline clinical characteristics of the study population are summarized in Table 1. The median age was 62 years in both the control and Nexpowder groups, with no significant difference (62 [37–77] vs. 62 [42–78]; p = 0.124). The proportions of patients receiving antiplatelet or anticoagulant therapy were similar between groups (17.5% vs. 17.1%; p = 1.000). Although the control group showed a trend toward a higher WBC count (6950/μL [3870–14 340] vs. 5670/μL [3190–9170]), the difference was not statistically significant. Tumor characteristics are presented in Table 2. In both groups, the most common tumor location was the ascending colon (19 [47.5%] vs. 19 [54.3%]; p = 0.623). Median tumor size was 32 mm (range, 20–65) in the control group and 33 mm (range, 20–50) in the Nexpowder group, with no significant difference. En bloc resection rates were 87.5% in the control group and 97.1% in the Nexpowder group (p = 0.206). Total ESD procedure time tended to be longer in the control group (45 min [15–111]) than in the Nexpowder group (30 min [14–100]), although this difference did not reach statistical significance. The proportion of T1a adenocarcinoma was slightly higher in the Nexpowder group (12.5% vs. 22.9%; p = 0.256), but the difference was not statistically significant. TABLE 1Baseline clinical characteristics of patients.VariablesControl group (n = 40)Nexpowder group (n = 35) p Age (year)62 (37–77)62 (42–78)0.124Sex (male), n (%)20 (50.0)17 (48.6)1.000Comorbidities, n (%)26 (65)20 (57.1)0.357DM6 (15.0)10 (28.6)HTN14 (35.0)15 (42.9)CKD1 (2.5)0 (0.0)Liver cirrhosis0 (0.0)0 (0.0)Cardiovascular disease5 (12.5)4 (11.5)Medication, n (%)7 (17.5)6 (17.1)1.000Anticoagulant1 (2.5)1 (2.9)Antiplatelet agent6 (15.0)5 (14.3)Dual antiplatelet agents1 (2.5)1 (2.9)WBC (1000/μL)6950 (3870–14 340)5670 (3190–9170)0.086Hb (g/dL)14.0 (12.2–17.0)13.1 (9.3–16.7)0.185Platelet count (1000/μL)207 (55–340)244 (116–330)0.318PTs (INR)0.96 (0.70–1.26)0.99 (0.86–1.13)0.157Albumin (mg/dL)4.4 (3.8–5.0)4.4 (3.8–5.1)0.171BUN (mg/dL)13.2 (8.8–28.8)12.3 (6.5–25.2)0.254Cr (mg/dL)0.80 (0.36–2.75)0.71 (0.56–1.36)0.171 Note: Data are expressed as median (range) for continuous variables and number (%) for categorical variables. p values were calculated using the Student's t‐test or Mann–Whitney U test for continuous variables and the Chi‐square test or Fisher's exact test for categorical variables.Abbreviations: BUN, blood urea nitrogen; CKD, chronic kidney disease; Cr, creatinine; DM, diabetes mellitus; Hb, hemoglobin; HTN, hypertension; PTs, prothrombin time. Baseline clinical characteristics of patients. Note: Data are expressed as median (range) for continuous variables and number (%) for categorical variables. p values were calculated using the Student's t‐test or Mann–Whitney U test for continuous variables and the Chi‐square test or Fisher's exact test for categorical variables. Abbreviations: BUN, blood urea nitrogen; CKD, chronic kidney disease; Cr, creatinine; DM, diabetes mellitus; Hb, hemoglobin; HTN, hypertension; PTs, prothrombin time. TABLE 2Characteristics of lesions.VariablesControl group (n = 40)Nexpowder group (n = 35) p Location of tumor, n (%)0.623Cecum12 (30.0)7 (20.0)Ascending colon19 (47.5)19 (54.3)Transverse colon9 (22.5)9 (25.7)Paris classification, n (%)0.494LST‐G26 (65.0)19 (54.3)LST‐NG12 (30.0)15 (42.9)Is2 (5.0)0 (0.0)Other (IIa + IIc, Ip + IIa)0 (0.0)1 (2.9)Histologic type of tumor, n (%)0.256Low‐grade adenoma22 (55.0)16 (45.7)High‐grade adenoma5 (12.5)8 (22.9)Sessile serrated lesion8 (20.0)3 (8.6)Adenocarcinoma (T1a)5 (12.5)8 (22.9)Size of tumor in mm # 32 (20–65)33 (20–50)0.329Resection, n (%)0.206En bloc35 (87.5)34 (97.1)Piecemeal5 (12.5)1 (2.9)Time of procedure in min § 45 (15–111)30 (14–100)0.529 Note: Data are expressed as median (range) for continuous variables and number (%) for categorical variables. p values were calculated using the Student's t‐test or Mann–Whitney U test for continuous variables, and the Chi‐square test or Fisher's exact test for categorical variables.Abbreviations: LST‐G, lateral spreading tumor–granular; LST‐NG, lateral spreading tumor–nongranular. # Largest diameter. § Total procedure time was defined as the time from the first mucosal incision to complete resection of the lesion. Characteristics of lesions. Note: Data are expressed as median (range) for continuous variables and number (%) for categorical variables. p values were calculated using the Student's t‐test or Mann–Whitney U test for continuous variables, and the Chi‐square test or Fisher's exact test for categorical variables. Abbreviations: LST‐G, lateral spreading tumor–granular; LST‐NG, lateral spreading tumor–nongranular. Largest diameter. Total procedure time was defined as the time from the first mucosal incision to complete resection of the lesion. Overall Clinical Outcomes The overall clinical outcomes are summarized in Table 3. The incidence of PECS, the primary endpoint, was significantly higher in the control group than the Nexpowder group (20.0% [8/40], 95% CI 9.9–34.2 vs. 2.9% [1/35], 95% CI 0.3–12.6, p = 0.032; Figure 4). No cases of delayed bleeding were observed in either group, and no complications related to powder application, such as perforation, colonic obstruction, or embolization occurred. TABLE 3Study outcomes.VariablesControl group (n = 40)Nexpowder group (n = 35) p PECS, n (% [95% CI])8 (20.0 [9.9–34.2])1 (2.9 [0.3–12.6])0.032Abdominal pain (≥NRS 4), n (% [95% CI])9 (22.5 [11.8–37.1])2 (5.7 [1.2–17.1])0.053Fever (≥ 37.5°C), n (% [95% CI])9 (22.5 [11.8–37.1])1 (2.9 [0.3–12.6])0.016WBC count (increase/μL) n (% [95% CI])9 (22.5 [11.8–37.1])6 (17.1 [7.7–32.8])0.561CRP increase over 1 mg/dL, n (% [95% CI])11 (27.5 [16.0–43.5])6 (17.1 [7.7–32.8])0.406Powder‐associated adverse event, n (%)Colonic obstruction0 (0.0)—Perforation0 (0.0)—Infection0 (0.0)—Embolization0 (0.0)— Note: Data are expressed as median (range) for continuous variables and number (%) for categorical variables. p values were calculated using the Student's t‐test or Mann–Whitney U test for continuous variables and the Chi‐square test or Fisher's exact test for categorical variables.Abbreviations: CI, confidence interval; NRS, numerical rating scale; PECS, post‐ESD coagulation syndrome. Study outcomes. Note: Data are expressed as median (range) for continuous variables and number (%) for categorical variables. p values were calculated using the Student's t‐test or Mann–Whitney U test for continuous variables and the Chi‐square test or Fisher's exact test for categorical variables. Abbreviations: CI, confidence interval; NRS, numerical rating scale; PECS, post‐ESD coagulation syndrome. Comparison of PECS incidence between the control and Nexpowder groups. After adjusting for potential confounders, multivariable logistic regression analysis revealed that the application of Nexpowder was independently associated with a significantly lower risk of PECS (OR 0.17, 95% CI 0.04–0.75, p = 0.019; Table 4). TABLE 4Univariable and multivariable logistic regression analysis for factors associated with PECS.VariablesUnivariable analysisMultivariable analysisOR (95% CI) p OR (95% CI) p Age1.04 [0.95–1.13]0.4130.97 [0.91–1.03]0.341Sex (male)1.22 [0.39–3.80]0.7291.64 [0.43–6.21]0.465Medication (antiplatelet and/or anticoagulant agents)0.29 [0.03–2.39]0.2480.23 [0.02–2.17]0.199Tumor size1.01 (0.96–1.06)0.8190.97 [0.91–1.03]0.275En bloc resection0.46 [0.08–2.81]0.4040.60 [0.09–3.90]0.595Time of procedure1.00 [0.98–1.02]0.7930.99 [0.97–1.02]0.642Use of Nexpowder0.22 [0.06–0.86]0.0290.17 [0.04–0.75]0.019 Note: Event: PECS (n = 9, 12.0%).Abbreviations: CI, confidence interval; OR, odds ratio; PECS, post ESD coagulation syndrome. Univariable and multivariable logistic regression analysis for factors associated with PECS. Note: Event: PECS (n = 9, 12.0%). Abbreviations: CI, confidence interval; OR, odds ratio; PECS, post ESD coagulation syndrome. All patients who developed PECS were managed conservatively with bowel rest and antibiotics. Fever and abdominal pain resolved within 3 days, and no surgical interventions were required. Three patients with persistent fever and unresolved abdominal pain after 2 days of antibiotics underwent computed tomography (CT) scans; none showed evidence of peritoneal or periluminal free air. In all 35 patients receiving Nexpowder, the post‐ESD ulcer base was fully covered, achieving a 100% coverage rate (Figure 3). Although some patients had elevated CRP levels, those without fever or abdominal pain were not diagnosed with PECS and were discharged without antibiotics. These cases accounted for 2 of 11 patients (18.2%) in the control group and 5 of 6 patients (83.3%) in the Nexpowder group. Discussion To our knowledge, this is the first multicenter study demonstrating the association between prophylactic application of a topical hemostatic agent and the reduced incidence of PECS in a high‐risk population. Among patients undergoing ESD for large, nonpedunculated lesions in the proximal colon, Nexpowder use was associated with a significant reduction in PECS from 20.0% in the control group to 2.9% (p = 0.032). While this primary outcome was significant, the reduction did not translate into statistically significant differences in abdominal pain or the magnitude of inflammatory marker elevation. PECS is caused by transmural electrothermal injury, which is inevitable to some degree during ESD [23]. Key risk factors—including female sex, right‐sided colonic location (particularly the cecum), large lesion size, and prolonged procedure time—align with the high‐risk profile of our cohort [25, 26]. Despite the development of predictive models, a gap remains between risk identification and effective prevention [10]. In the absence of a specific prophylactic method, our findings suggest that Nexpowder may offer a simple and reliable strategy to prevent PECS, particularly in high‐risk patients and may hold considerable clinical relevance. Although statistically nonsignificant, the control group tended to have longer procedure times and a higher proportion of tumors located in the cecum. Both prolonged procedure time and cecal location are well‐recognized risk factors for PECS development [27]. Therefore, despite the lack of statistical significance, their potential contribution to the higher PECS incidence in the control group cannot be completely excluded. If these variables had been evenly distributed, their influence on PECS occurrence might have been more pronounced. However, in this study, the control group had a higher rate of piecemeal resection, most of which involved cecal lesions. Moreover, the number of procedures lasting more than 60 min was similar between groups (27.5% [11/40] in the control group vs. 28.6% [10/35] in the Nexpowder group), and the proportion of T1a cancers was actually higher in the Nexpowder group. Taken together, these findings suggest that the slightly longer median procedure time and higher proportion of cecal lesions in the control group are unlikely to have compromised the reliability of our results. The preventive effect of Nexpowder on PECS may be explained by several mechanisms. First, Nexpowder forms a physical barrier that provides immediate and sustained protection for the post‐ESD ulcer. While its duration may vary, the gel generally remains adherent for approximately 24 h and up to 48 h [18], shielding the exposed submucosa from chemical and mechanical irritants, such as the fecal stream, during a period of peak tissue vulnerability. Second, Nexpowder's safety is well established; its biocompatible components have been evaluated in prior studies, minimizing concerns about adverse tissue reactions [19, 28, 29, 30]. Third, its delivery system allows gradual and controlled application, enabling complete coverage of the entire mucosal defect, regardless of size or shape. With a maximal spray duration of 60 s, the operator can achieve thorough and controlled application, ensuring full coverage of the post‐ESD ulcer base. Also, ESD‐induced mucosal injuries are exposed to the high bacterial load of the colon [26, 31]. One intriguing hypothesis is that Nexpowder may exert antimicrobial effects. Its components, ε‐poly‐l‐lysine and oxidized dextran, are known to have antimicrobial activity in vitro [22, 23], which could theoretically protect the exposed submucosal layer from bacterial contamination. However, while this is an interesting consideration, the primary clinical benefits of Nexpowder likely arise from its established physical and hemostatic mechanisms rather than these speculative antimicrobial effects. Further mechanistic studies are needed to evaluate any additional properties. The strengths of our study include its novelty as the first multicenter investigation specifically assessing a topical agent for PECS prevention. Additionally, we focused on a clinically relevant, high‐risk population undergoing proximal colon ESD, enhancing the significance of our findings. Despite these strengths, several limitations should be acknowledged. First, the retrospective design is a major limitation. Second, although this was a multicenter study and all participating endoscopists had experience with more than 100 colorectal ESD procedures, variations in expertise may still have existed. Another limitation is the subjectivity in diagnosing PECS, which relied on clinical signs and the decision to initiate antibiotics, without mandatory abdominopelvic CT. This could have led to over‐ or under‐diagnosis. However, patients who did not improve within 3 days underwent CT scanning, and no perforations were detected. Moreover, all patients experienced resolution of abdominal pain, fever, and leukocytosis within 2 days of antibiotics, supporting the accuracy of PECS diagnosis and the exclusion of perforation cases. Finally, the relatively small sample size in the Nexpowder group may have reduced statistical power. Nevertheless, valid analyses were conducted using nonparametric tests, and the observed effects remained statistically significant. We therefore believe this limitation has minimal impact on the robustness of our results. Conclusions In conclusion, prophylactic application of Nexpowder was associated with a significant reduction in the incidence of PECS after ESD for high‐risk colorectal lesions, with a rate of 2.9% in the Nexpowder group compared with 20% in the control group. These findings provide important clinical evidence supporting the use of a topical barrier agent as a promising strategy to prevent PECS after colon ESD. To further validate these results, a large‐scale, prospective, randomized controlled trial is currently underway. Funding The authors have nothing to report. Ethics Statement The study protocol received approval from the institutional review board of our institution (SCHBC 2025‐07‐012). Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Video S1: Nexpowder application on ESD ulcer.